Drugs / IMP7068
last change Oct 2023 re-read 3 minutes ago

IMP7068

targets WEE1 via inhibition

Developed for
cancer
Investigated by
Covance · Impact Therapeutics, Inc.

Trials 1

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04768868 Feb 2021 → Apr 2023 cancer Impact Therapeutics, Inc. Unknown No outcome recorded

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2023-10-24 Impact Therapeutics, Inc. Results 英派药业在欧洲肿瘤内科学会 (ESMO) 大会上公布了WEE1 抑制剂IMP7068的初步研究数据 impacttherapeutics.com ↗
2023年10月23日,英派药业在 2023 年欧洲肿瘤内科学会大会上, 以口头报告的形式公布了WEE1 抑制剂IMP7068的初步研究数据。
2023-04-18 Impact Therapeutics, Inc. Results 英派药业宣布在2023年美国癌症研究协会(AACR)会上发表WEE1抑制剂IMP7068相关数据 impacttherapeutics.com ↗
与AZD1775相比,IMP7068显示出更高的WEE1/PLK1选择性(>435倍),同时IMP7068对多种肿瘤细胞系展现出很强的细胞毒性。
2022-09-10 Impact Therapeutics, Inc. Results 英派药业在2022年欧洲肿瘤内科学会年会(ESMO)上发表Wee1抑制剂IMP7068单药的I期临床数据 impacttherapeutics.com ↗
数据显示IMP7068具有良好的耐受性和对WEE1的抑制作用,其药代动力学和药效学特征与剂量水平一致。
2021-02-09 Impact Therapeutics, Inc. Regulatory 英派药业Wee1抑制剂IMP7068获批进入中国临床试验 impacttherapeutics.com ↗
英派药业今日宣布,公司自主研发的Wee1抑制剂IMP7068获得中国国家药品监督管理局(NMPA)临床试验批准,将在中国启动临床试验。

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IMP7068 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04768868 ↗
Action Inhibit “WEE1 inhibitor IMP7068” NCT04768868 ↗
Target WEE1 “WEE1 inhibitor IMP7068” NCT04768868 ↗